Cargando…
Recent advances in the development of breast cancer vaccines
The manipulation of the immune system through the administration of a vaccine to direct an effective and long-lasting immune response against breast cancer (BC) cells is an attractive strategy. Vaccines would have several theoretical advantages over standard therapies, including low toxicities, high...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204811/ https://www.ncbi.nlm.nih.gov/pubmed/25339848 http://dx.doi.org/10.2147/BCTT.S38428 |
_version_ | 1782340603706605568 |
---|---|
author | Milani, Andrea Sangiolo, Dario Aglietta, Massimo Valabrega, Giorgio |
author_facet | Milani, Andrea Sangiolo, Dario Aglietta, Massimo Valabrega, Giorgio |
author_sort | Milani, Andrea |
collection | PubMed |
description | The manipulation of the immune system through the administration of a vaccine to direct an effective and long-lasting immune response against breast cancer (BC) cells is an attractive strategy. Vaccines would have several theoretical advantages over standard therapies, including low toxicities, high specificity, and long-lasting efficacy due to the establishment of immunological memory. However, BC vaccines have failed to demonstrate meaningful results in clinical trials so far. This reflects the intrinsic difficulty in breaking the complex immune-escaping mechanisms developed by cancer cells. New vaccines should be able to elicit complex immunologic response involving multiple immune effectors such as cytotoxic and antibody-secreting B cells, innate immunity effectors, and memory cells. Moreover, especially in patients with large tumor burdens and metastatic disease, combining vaccines with other strategies, such as systemic BC therapies, passive immunotherapy, or immunomodulatory agents, could increase the effectiveness of each approach. Here, we review recent advances in BC vaccines, focusing on suitable targets and innovative strategies. We report results of most recent trials investigating active immunotherapy in BC and provide possible future perspectives in this field of research. |
format | Online Article Text |
id | pubmed-4204811 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-42048112014-10-22 Recent advances in the development of breast cancer vaccines Milani, Andrea Sangiolo, Dario Aglietta, Massimo Valabrega, Giorgio Breast Cancer (Dove Med Press) Review The manipulation of the immune system through the administration of a vaccine to direct an effective and long-lasting immune response against breast cancer (BC) cells is an attractive strategy. Vaccines would have several theoretical advantages over standard therapies, including low toxicities, high specificity, and long-lasting efficacy due to the establishment of immunological memory. However, BC vaccines have failed to demonstrate meaningful results in clinical trials so far. This reflects the intrinsic difficulty in breaking the complex immune-escaping mechanisms developed by cancer cells. New vaccines should be able to elicit complex immunologic response involving multiple immune effectors such as cytotoxic and antibody-secreting B cells, innate immunity effectors, and memory cells. Moreover, especially in patients with large tumor burdens and metastatic disease, combining vaccines with other strategies, such as systemic BC therapies, passive immunotherapy, or immunomodulatory agents, could increase the effectiveness of each approach. Here, we review recent advances in BC vaccines, focusing on suitable targets and innovative strategies. We report results of most recent trials investigating active immunotherapy in BC and provide possible future perspectives in this field of research. Dove Medical Press 2014-10-14 /pmc/articles/PMC4204811/ /pubmed/25339848 http://dx.doi.org/10.2147/BCTT.S38428 Text en © 2014 Milani et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Milani, Andrea Sangiolo, Dario Aglietta, Massimo Valabrega, Giorgio Recent advances in the development of breast cancer vaccines |
title | Recent advances in the development of breast cancer vaccines |
title_full | Recent advances in the development of breast cancer vaccines |
title_fullStr | Recent advances in the development of breast cancer vaccines |
title_full_unstemmed | Recent advances in the development of breast cancer vaccines |
title_short | Recent advances in the development of breast cancer vaccines |
title_sort | recent advances in the development of breast cancer vaccines |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204811/ https://www.ncbi.nlm.nih.gov/pubmed/25339848 http://dx.doi.org/10.2147/BCTT.S38428 |
work_keys_str_mv | AT milaniandrea recentadvancesinthedevelopmentofbreastcancervaccines AT sangiolodario recentadvancesinthedevelopmentofbreastcancervaccines AT agliettamassimo recentadvancesinthedevelopmentofbreastcancervaccines AT valabregagiorgio recentadvancesinthedevelopmentofbreastcancervaccines |